BioCryst Pharma Raises FY2026 Sales Guidance from $690.000M-$715.000M to $715.000M-$730.000M vs $710.134M Est
Benzinga Newsdesk 12 hours ago
NewsGuidance
BioCryst Pharma (NASDAQ:BCRX) raises FY2026 sales outlook from $690.000 million-$715.000 million to $715.000 million-$730.000 million vs $710.134 million estimate.
BioCryst Pharma (NASDAQ:BCRX) raises FY2026 sales outlook from $690.000 million-$715.000 million to $715.000 million-$730.000 million vs $710.134 million estimate.